Squarepoint
AVIR icon

Squarepoint’s Atea Pharmaceuticals AVIR Stock Holding History

Squarepoint’s Portfolio AVIR Stock Details AVIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$136K Sell
29,316
-25,782
-47% -$128K ﹤0.01% 4147
2026
Q1 		$296K Buy
55,098
+35,787
+185% +$164K ﹤0.01% 3720
2025
Q4 		$68.9K Buy
+19,311
New +$61.4K ﹤0.01% 4097
2025
Q2 		– Sell
-15,756
Closed -$47.1K – 4476
2025
Q1 		$47.1K Sell
15,756
-34,994
-69% -$109K ﹤0.01% 4350
2024
Q4 		$170K Buy
50,750
+35,053
+223% +$116K ﹤0.01% 4533
2024
Q3 		$52.6K Buy
15,697
+1,057
+7% +$3.83K ﹤0.01% 3977
2024
Q2 		$48.5K Sell
14,640
-5,513
-27% -$20.6K ﹤0.01% 3908
2024
Q1 		$81.4K Buy
+20,153
New +$78.9K ﹤0.01% 3826
2023
Q4 		– Sell
-41,308
Closed -$124K – 3997
2023
Q3 		$124K Buy
41,308
+22,117
+115% +$75.3K ﹤0.01% 3529
2023
Q2 		$71.8K Sell
19,191
-3,586
-16% -$13.4K ﹤0.01% 3405
2023
Q1 		$76.3K Sell
22,777
-16,237
-42% -$65.9K ﹤0.01% 3016
2022
Q4 		$188K Buy
+39,014
New +$197K ﹤0.01% 2808
2022
Q1 		– Sell
-213,220
Closed -$1.91M – 2806
2021
Q4 		$1.91M Buy
+213,220
New +$3.32M 0.01% 1297

Other funds holding AVIR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Squarepoint's AVIR Position: Q2 2026 in Review

Squarepoint reduced its Atea Pharmaceuticals (AVIR) stake by 47% in Q2 2026, selling an estimated $128K and leaving 29,316 shares worth $136K. The position accounts for ﹤0.01% of the portfolio, ranked #4147.

Squarepoint first reported a position in AVIR in Q4 2021 and has held it in 13 quarters since. The position peaked at $1.91M in Q4 2021. 125 funds tracked by Wall St. Rank hold AVIR as of Q2 2026.

  • Squarepoint held 29,316 shares of Atea Pharmaceuticals worth $136K as of Q2 2026.
  • Squarepoint sold 25,782 Atea Pharmaceuticals shares in Q2 2026, an estimated $128K.
  • Atea Pharmaceuticals made up ﹤0.01% of Squarepoint's portfolio in Q2 2026, its #4147 holding.
  • Squarepoint first reported a position in Atea Pharmaceuticals in Q4 2021 and has held it in 13 quarters since.
  • Squarepoint's Atea Pharmaceuticals position peaked at $1.91M in Q4 2021.
  • 125 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q2 2026.

Based on Squarepoint's 13F filing for Q2 2026, filed 14 Aug 2026.